标题
Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection
作者
关键词
-
出版物
DRUGS
Volume 80, Issue 1, Pages 61-72
出版商
Springer Science and Business Media LLC
发表日期
2019-12-21
DOI
10.1007/s40265-019-01247-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice
- (2019) Gianmaria Baldin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy
- (2019) Jason Gillman et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Adherence to HIV treatment regimens: systematic literature review and meta-analysis
- (2019) Frederick Altice et al. Patient Preference and Adherence
- A systematic review of the genetic mechanisms of dolutegravir resistance
- (2019) Soo-Yon Rhee et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients
- (2019) Matthew Radford et al. AIDS
- Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a 2-Drug Antiretroviral Therapy for HIV-1 Infection
- (2019) Marta Boffito et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- DOLAMA study
- (2019) Carmen Hidalgo-Tenorio et al. MEDICINE
- Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: latest evidences from the literature on their efficacy and safety
- (2019) Valeria Cento et al. Journal of Global Antimicrobial Resistance
- Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review
- (2018) Rosaleen Boswell et al. ANNALS OF PHARMACOTHERAPY
- Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial
- (2018) Jose L Blanco et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- New Strategies of ARV: the Road to Simplification
- (2018) Rosa de Miguel Buckley et al. Current HIV/AIDS Reports
- HIV Clinical Updates: New Single-Tablet Regimens
- (2018) Jamielynn C. Sebaaly et al. ANNALS OF PHARMACOTHERAPY
- Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA
- (2018) Amesika N Nyaku et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)
- (2018) Véronique Joly et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
- (2018) Pedro Cahn et al. LANCET
- PIN64 - DOLUTEGRAVIR PLUS LAMIVUDINE FOR THE TREATMENT OF NAÏVE ADULTS LIVING WITH HIV-1: A UK COST-MINIMIZATION ANALYSIS
- (2018) T. Ward et al. VALUE IN HEALTH
- HIV drug resistance against strand transfer integrase inhibitors
- (2017) Kaitlin Anstett et al. Retrovirology
- Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
- (2015) Sean E. Collins et al. DRUGS
- Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients
- (2015) Slim Fourati et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and Adults
- (2014) Paul L. McCormack DRUGS
- Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes
- (2014) M. Pollicita et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics
- (2013) Felix DeAnda et al. PLoS One
- Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
- (2011) Kendra E. Hightower et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)
- (2011) S. Hare et al. MOLECULAR PHARMACOLOGY
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now